Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus paclitaxel (albumin-bound) and carboplatin as neoadjuvant therapy for locally advanced head and neck squamous cell carcinoma
ChiCTR2400091171Phase 2Completed
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in head and neck squamous cell carcinoma (HNSCC), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Objective response rate. Started Jun 2024; status: completed.
02
Drugs
adebrelimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2400091171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091171.